Submitted by administrator on
According to drug manufacturer Novartis, 2,400 patients a year are treated for macular oedema as a result of branch retinal vein occlusion in Scotland.
The condition can have debilitating affects on a patients life as the visual impairment takes away their capability to undertake and complete simple every day tasks.
In Scotland, patients have been formerly treated for macular oedema with the drug Ranibizumab, but as of this month, the Scottish Medicines Consortium have released a statement that the eye drug Lucentis has been accepted as an alternative drug option for visually impaired people with the condition brought about as a result of branch retinal vein occlusion. Up to now, patients with BRVO were unable to have access to this treatment, which can reportedly provide a fast and significant gains in vision.